Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and China, has received approval from the US Food and Drug Administration (FDA) to initiate a clinical study for its investigational drug ²²⁵Ac-FL-020 in patients with metastatic castration-resistant prostate cancer (mCRPC).
²²⁵Ac-FL-020 is a PSMA (prostate-specific membrane antigen) targeted radionuclide drug conjugate (RDC) with the potential to be best-in-class. In preclinical models, ²²⁵Ac-FL-020, once radiolabeled, has demonstrated superior in vivo distribution characteristics, including high levels and sustained tumor uptake, coupled with rapid systemic clearance. In the LNCaP xenograft mouse model, the drug candidate exhibited excellent anti-tumor activity and a favorable safety profile.- Flcube.com
